malignant tumor
Conditions
Interventions
Intervention Group:PRO-based comprehensive pharmaceutical care
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed malignant tumors (including both solid tumors and hematologic malignancies), regardless of disease stage, received at least one dose of immune checkpoint inhibitor (ICI) therapy; 2. Aged >=18 years; 3. Any gender; 4. Life expectancy >=3 months; 5. Able to complete electronic or paper-based PRO questionnaires independently or with assistance (e.g., possessing smartphone proficiency or having caregiver support).
Exclusion criteria
Exclusion criteria: 1. Cognitive or language impairments preventing reliable PRO completion (e.g., dementia, aphasia); 2. For participants with neurodegenerative disorders (e.g., Alzheimer’s disease), history of stroke, or psychiatric disorders, when montreal Cognitive Assessment (MoCA) score <=25 will be excluded; 3. Participants with language barriers including inability to communicate in Mandarin Chinese and diagnosed aphasia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Early detection rate of irAEs; | — |
Secondary
| Measure | Time frame |
|---|---|
| Compliance with the Treatment Plan/Regimen;Symptoms burden change;Adherence to Patient-Reported Outcome Questionnaire (PRO) Completion;Quality of Life; | — |
Countries
China
Contacts
Public ContactZhan Mei
West China Hospital of Sichuan University
Outcome results
None listed